Harbin Pharmaceutical announced on the evening of October 11 that the company recently received a Notice of Case Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. According to an announcement disclosed by the company at the end of August, the 2026 interim results briefing scheduled for September 10, 2026, still included director and president Lu Chuanyou among the participants. Lu Chuanyou previously served as chief engineer, executive deputy factory director, factory director, and party secretary of Harbin Pharmaceutical Group No. 6 Pharmaceutical Factory, party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd., and deputy general manager of Harbin Pharmaceutical Group Co., Ltd. Since 2023, he has served as president and member of the strategy committee of Harbin Pharmaceutical Group Co., Ltd. Harbin Pharmaceutical stated that the company has a sound organizational structure and a standardized governance system, has made proper arrangements for related work, and that the chairman, other directors, and other senior management are performing their duties normally. The board of directors is operating normally, production and operations are normal, and the announced matter will not have a material impact on the company's production, operations, or management. The company's 2026 interim report showed that first-half operating revenue reached 8.296 billion yuan, up 2.10 percent year on year; net profit attributable to shareholders of the listed company reached 410 million yuan, up 57.99 percent year on year; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses reached 355 million yuan, up 45.39 percent year on year.
Harbin Pharmaceutical Group Co LtdDirector and president Lu Chuanyou placed on file and subject to detention by supervisory authorities, a legal/regulatory action against a top executive.
